logo
I'm a cardiologist — this overprescribed drug taken by millions of people is toxic for your heart

I'm a cardiologist — this overprescribed drug taken by millions of people is toxic for your heart

Yahoo10-04-2025
This little pill — taken by adults and children alike — might just be a prescription for heart disease.
Dr. Evan Levine is an experienced cardiologist in Scarsdale, New York, who also runs a very popular TikTok channel, where he gets real about everything from heart attacks and health care quacks to the truth about your favorite Starbucks drink.
Speaking to The Post, the veteran heart doctor tackled a drug that is commonly prescribed to help children perform better on tests and sports — a phenomenon he calls 'borderline child abuse.'
'There are two classes of stimulants for ADHD,' Levine said.
'One is the Ritalin-derived drugs called methylphenidates — Ritalin and Concerta are the most popular — and the other is the amphetamine class like Adderall and Vyvanse.'
Both types, he said, 'increase the levels of norepinephrine in the blood, which can lead to slightly higher blood pressure and a mild increase in risk of arrhythmias.'
That might sound minor, but new research and common-sense questions have Levine sounding the alarm.
'In 2011, the Food and Drug Administration used a study to confirm the safety of these stimulant medications and they concluded — among young and middle-aged adults — [that there is] no increase in cardiovascular events,' Levine pointed out.
'But the study clearly states the average follow-up was only 1.3 years,' he added. 'So, yeah, young healthy people have no risk at 1.3 years with elevated norepinephrine levels in their blood.'
Here comes the however.
'We know that very elevated levels of norepinephrine for years, like in people with adrenal tumors and heart failure, can adversely affect the heart — levels are much higher here,' Levine said.
'What if a child takes this for 20 years? The FDA never commented on this. Or an elderly patient takes this — or anyone at risk, people with congenital heart conditions like a bicuspid aortic valve, which 1.5% of the population has and are at risk for aortic aneurysms? The FDA never did their job.'
And now? The longer-term data is starting to back him up.
'In April 2024, they find that when you follow them up for eight years, young healthy people aged 20 to 40, they have a 57% higher risk than young healthy people not on these meds,' Levine said.
'It ends up that 1/500 of these patients were diagnosed with a cardiomyopathy.'
Levine, who also tackled the subject on TikTok, noted that the sheer volume of Americans taking these meds could be a ticking time bomb — recent data suggested 1 in 9 kids these days have been diagnosed with ADHD.
'The numbers of young adults on this since childhood can be significant,' he said.
But it's not just kids: A recent study showed 1 in 17 adults have been diagnosed with ADHD, and some experts questioned whether or not all of these cases are legitimate.
Levine said people are taking it without an ADHD diagnosis, only to help them 'focus better on exams or perform better in sports.'
Plus, he added, the drugs may have a greater risk for adults who may have hypertension or underlying heart disease.
Telehealth services have supercharged the trend, Levine warned — potentially making the drugs available to anyone with a credit card and Wi-Fi access.
'Who is vetting these services? 'Hi, my name is Evan and I cannot concentrate and need some Adderall. Thank you,'' he said.
According to Levine, what's lacking is comprehensive mental health care and careful consideration of non-stimulant options.
'With better behavioral health, available psychiatric evaluation and alternatives like non-stimulants, of course the amount of prescriptions for these drugs will diminish,' he said.
Levine pointed out that these meds are taken seriously — even banned — in certain fields unless a formal diagnosis is proven.
'In Olympic sports, you need to apply for an exemption and demonstrate you have ADHD. Otherwise, you are disqualified,' he said.
'One can only guess there are some that claim a diagnosis to improve their ability and concentration in a sport.'
So, what now? For Levine, the message is simple: ADHD should absolutely be treated — but with more caution, more oversight and less blind trust in pills.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How 9 minutes of daily HIIT may improve kids' brain function and learning, according to research
How 9 minutes of daily HIIT may improve kids' brain function and learning, according to research

Tom's Guide

time3 hours ago

  • Tom's Guide

How 9 minutes of daily HIIT may improve kids' brain function and learning, according to research

Kids' attention spans aren't exactly getting any longer. Some can't even make it to the end of a 10-second TikTok without swiping away. To be honest, I'm also guilty of this sometimes. But if you can hold their focus for nine whole minutes of exercise, scientists think they've found a little hack that could help children concentrate better in class. Researchers from the University of Eastern Finland studied how short bursts of physical activity could influence a child's ability to focus. They asked seven- to 13-year-olds to complete a simple nine-minute workout before sitting down to cognitive tests. The results? Kids who exercised performed better on tasks that required sustained attention and working memory compared to those who stayed seated. If you are a parent looking to move more and encourage your children to do the same, our guide to the best fitness trackers can help you keep track of your activity levels and stay motivated. The study found that nine minutes of high-intensity interval exercise (HIIE) can help children focus better and improve performance on cognitive tasks. For reference, this activity took place in a school setting before tests. The researchers suggest the boost in focus may come from the temporary increase in heart rate and blood flow, which delivers more oxygen and nutrients to the brain, along with the release of neurotransmitters that support alertness and cognitive function. If you are a parent and want to try using this at home to help your child focus, settle down after school, or tackle homework more easily, the principle is pretty flexible. You don't need a full PE class. Just nine minutes of fun, energetic high-intensity interval exercise (HIIE) that gets your child's heart rate up could make a difference. This could be a quick dance to a favorite song or two, a short obstacle course in the living room, or a few laps around the yard. It's important to note that this research does not provide a guaranteed solution for improving focus in all children, and every child's needs and circumstances are different. The study shows a potential benefit in a classroom setting, but individual results may vary. Still, making exercise a fun and regular part of family life can support both the body and mind. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.

TMO Receives FDA Approval for Oncomine Dx Target Test
TMO Receives FDA Approval for Oncomine Dx Target Test

Yahoo

time4 hours ago

  • Yahoo

TMO Receives FDA Approval for Oncomine Dx Target Test

Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers

Epoch Times

time5 hours ago

  • Epoch Times

FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers

Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store